← Back to search
ESSENTIAL ACCESS HEALTH
LOS ANGELES, CA, 90010
UnclaimedClaim this profile (free)
Prime contracting experience
3 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF TITLE: CLINICAL EVALUATION OF NOVEL PRODUCTS FOR FEMALE CONTRACEPTION, MAIN STUDY EFFECTIVE DATE: 9/19/2014 PERIOD OF PERFORMANCE: 9/19/2014-9/18/2017 | HHSN275201300022IUSAspending | $743,362 | Aug 27, 2026 | Sep 19, 2014 – Jan 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | OVAPRENE PHASE 1: PROTOCOL FINALIZATION, REGULATORY APPROVAL, START-UP, AND COMMENCEMENT OF RECRUITMENT, SCREENING, AND ENROLLMENT FOR THE OVAPRENE VAGINAL DEVICE CLINICAL TRIAL | 75N94020D00015USAspending | $349,327 | Mar 26, 2025 | Sep 28, 2023 – May 30, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF A MULTI-CENTER, RANDOMIZED STUDY TO EVALUATE THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE, CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL LOW DOSE ULIPRISTAL ACETATE | HHSN275201300022IUSAspending | $1,420,019 | Nov 4, 2024 | Jul 16, 2013 – Mar 31, 2022 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.